Combining yttrium 90-labeled ibritumomab tiuxetan with high-dose chemotherapy and stem cell support in patients with relapsed non-Hodgkin's lymphoma

Jane N. Winter

doi:10.3816/CLM.2004.s.005

Combining yttrium 90-labeled ibritumomab tiuxetan with high-dose chemotherapy and stem cell support in patients with relapsed non-Hodgkin's lymphoma

Jane N. Winter^*

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Article › peer-review

26 Scopus citations

Abstract

Targeted radioimmunotherapy, including yttrium 90-labeled ibritumomab tiuxetan (Zevalin®) and iodine 1131 tositumomab (Bexxar®), has the potential to increase the cure rate for patients with CD20⁺ B-cell malignancies who are undergoing autologous hematopoietic stem cell transplantation. The results of phase I and II trials suggest that radioimmunoconjugates can be safely combined with high-dose chemotherapy, although the optimal approach remains to be established. This review focuses on the use of ⁹⁰Y ibritumomab tiuxetan combined with high-dose chemotherapy in the setting of autologous hematopoietic stem cell transplantation.

Original language	English (US)
Pages (from-to)	S22-S26
Journal	Clinical Lymphoma
Volume	5
Issue number	SUPPL. 1
DOIs	https://doi.org/10.3816/CLM.2004.s.005
State	Published - Oct 2004

Keywords

Autologous stem cell transplantation
Radioimmunotherapy
Targeted therapy

ASJC Scopus subject areas

Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3816/CLM.2004.s.005

Cite this

@article{4099a64d96024081989ae59d1f685173,

title = "Combining yttrium 90-labeled ibritumomab tiuxetan with high-dose chemotherapy and stem cell support in patients with relapsed non-Hodgkin's lymphoma",

abstract = "Targeted radioimmunotherapy, including yttrium 90-labeled ibritumomab tiuxetan (Zevalin{\textregistered}) and iodine 1131 tositumomab (Bexxar{\textregistered}), has the potential to increase the cure rate for patients with CD20+ B-cell malignancies who are undergoing autologous hematopoietic stem cell transplantation. The results of phase I and II trials suggest that radioimmunoconjugates can be safely combined with high-dose chemotherapy, although the optimal approach remains to be established. This review focuses on the use of 90Y ibritumomab tiuxetan combined with high-dose chemotherapy in the setting of autologous hematopoietic stem cell transplantation.",

keywords = "Autologous stem cell transplantation, Radioimmunotherapy, Targeted therapy",

author = "Winter, {Jane N.}",

year = "2004",

month = oct,

doi = "10.3816/CLM.2004.s.005",

language = "English (US)",

volume = "5",

pages = "S22--S26",

journal = "Clinical Lymphoma",

issn = "2152-2669",

publisher = "Cancer Media Group",

number = "SUPPL. 1",

}

TY - JOUR

T1 - Combining yttrium 90-labeled ibritumomab tiuxetan with high-dose chemotherapy and stem cell support in patients with relapsed non-Hodgkin's lymphoma

AU - Winter, Jane N.

PY - 2004/10

Y1 - 2004/10

N2 - Targeted radioimmunotherapy, including yttrium 90-labeled ibritumomab tiuxetan (Zevalin®) and iodine 1131 tositumomab (Bexxar®), has the potential to increase the cure rate for patients with CD20+ B-cell malignancies who are undergoing autologous hematopoietic stem cell transplantation. The results of phase I and II trials suggest that radioimmunoconjugates can be safely combined with high-dose chemotherapy, although the optimal approach remains to be established. This review focuses on the use of 90Y ibritumomab tiuxetan combined with high-dose chemotherapy in the setting of autologous hematopoietic stem cell transplantation.

AB - Targeted radioimmunotherapy, including yttrium 90-labeled ibritumomab tiuxetan (Zevalin®) and iodine 1131 tositumomab (Bexxar®), has the potential to increase the cure rate for patients with CD20+ B-cell malignancies who are undergoing autologous hematopoietic stem cell transplantation. The results of phase I and II trials suggest that radioimmunoconjugates can be safely combined with high-dose chemotherapy, although the optimal approach remains to be established. This review focuses on the use of 90Y ibritumomab tiuxetan combined with high-dose chemotherapy in the setting of autologous hematopoietic stem cell transplantation.

KW - Autologous stem cell transplantation

KW - Radioimmunotherapy

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=7944223710&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7944223710&partnerID=8YFLogxK

U2 - 10.3816/CLM.2004.s.005

DO - 10.3816/CLM.2004.s.005

M3 - Article

C2 - 15498146

AN - SCOPUS:7944223710

SN - 2152-2669

VL - 5

SP - S22-S26

JO - Clinical Lymphoma

JF - Clinical Lymphoma

IS - SUPPL. 1

ER -

Combining yttrium 90-labeled ibritumomab tiuxetan with high-dose chemotherapy and stem cell support in patients with relapsed non-Hodgkin's lymphoma

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this